CrystalGenomics secures USD2.6m in strategic equity investment from KSLSF.
M2 PHARMA-January 17, 2012-CrystalGenomics secures USD2.6m in strategic equity investment from KSLSF(C)2012 M2 COMMUNICATIONS
17 January 2012 - South Korean biopharmaceutical company CrystalGenomics Inc said on Friday it had secured KRW3bn (USD2.6m/EUR2.1m) in a private placement to the Korea Seoul Life Science Fund (KSLSF).
This is the third time within the past month that the company has secured capital following a KRW10bn bond issuance to KDB Capital and another KRW10bn in bonds issued to Tube Investment.
The company said it will use proceeds to support its R&D including three clinical stage therapeutic programmes.
(KRW1000 = USD0.873/EUR0.685)
((Comments on this story may be sent to firstname.lastname@example.org))